TICKERNERD
Menu
NCELNCELHealthcare · Biotechnology

NCEL Stock Forecast: NewCelX Ltd. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$3.04
+2.50% on the day

The 1 Wall Street analysts covering NewCelX Ltd. hold a median 12-month price target of $23 — +657.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 4 of 100 as at 7 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$16.5M
Ticker Nerd rank
4 / 100
Median analyst target
$23
Analysts covering
1
Total return, dividends reinvested
1W
−1.3%
1M
−9.4%
YTD
+59.7%
1Y
−83.4%
From 52W high
−83.8%
From 52W low
+61.4%
$2
$19
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NCEL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores NewCelX Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Oct 2026
4 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
89
Revisions
53
Momentum
13
Value
9
Growth
8
Accruals
8
Issuance
7
Quality
5
Volatility
4

Size (89): Smaller than most of the companies we track.

Volatility (4): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NCEL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NCEL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25Jan 26Apr 26Jul 26Oct 26NCELHigh $23Median $23Low $23

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $23Median $23High $23

The green dot is the last close — the median target sits +657.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 July 2026Laidlaw & Co.InitiatesBuy$23
13 July 2026Laidlaw & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NCEL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NCEL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, NewCelX Ltd. returned −83.4% against +17.4% for the S&P 500, dividends included.

NCEL vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26NCELS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NCEL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

NewCelX Ltd. (NCEL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
5.7×

Cheaper than 65% of US stocks

Price / sales
—
Price / book
2.6×

Cheaper than 35% of US stocks

EV / EBITDA
−3.8×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−114.5%

Higher than 12% of US stocks

Return on assets
−49.6%

Higher than 8% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

NewCelX Ltd. (NCEL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • NewCelX Ltd. has a market value of $16.5M and an enterprise value of $15.1M.

  • Shares outstanding: 4.8M.

  • Trailing P/E: 5.7×; forward P/E: −5.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • NewCelX Ltd. employs 9 people.

market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

NCEL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NCELNewCelX Ltd.$16.5M
4
BCDABioCardia, Inc.$16.2M
41
PTNPalatin Technologies, Inc.$16.2M
38
ICUSeastar Medical Holding Corp.$16.4M
24
ALLRAllarity Therapeutics, Inc.$15.8M
30
AEONAEON Biopharma, Inc.$15.5M
52
DAREDaré Bioscience, Inc.$15.3M
31

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own NewCelX Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NCEL news & analysis

NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes

GlobeNewsWire · 28 Sept 2026positive

NewCelX Ltd. management plans to attend the Breakthrough T1D Congress in Philadelphia, a step supporting the company's mission to develop a cure for Type 1 diabetes. The announcement was made via press release from Zurich on Sept. 28, 2026.

Why it matters — NCEL watchers would see the company's engagement at a major Type 1 diabetes industry event as demonstrating active commitment to advancing its research and development mission.

NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing

GlobeNewsWire · 31 July 2026positive

NewcelX announced a $1.4 million equity financing priced at a 20% premium, following a successful FDA pre-IND meeting for its lead Type 1 diabetes program.

Why it matters — The pricing at a premium signals strong investor confidence and the financing will support the advancement of NewcelX's lead Type 1 diabetes program.

FAQ

Frequently asked questions about NCEL stock

What is the NCEL stock price forecast for 2026-2027?

The 1 Wall Street analysts covering NewCelX Ltd. have a median 12-month price target of $23, with estimates ranging from $23 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NCEL stock a buy right now?

Of the 1 analysts covering NewCelX Ltd., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NewCelX Ltd. 4 out of 100 across roughly 4,600 US stocks as at 7 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NCEL?

As at 7 Oct 2026, NewCelX Ltd. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).

Will NCEL stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +657.8% from the last close, and Ticker Nerd's factor model ranks NewCelX Ltd. 4 out of 100 as at 7 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NCEL stock forecast for 2030?

No analyst covering NewCelX Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NCEL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $23 over the next 12 months.

How has NCEL stock performed over the past year?

NewCelX Ltd. returned -83.4% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does NewCelX Ltd. do?

NewcelX Ltd. is a Switzerland-based biopharmaceutical company focused on developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases.

What is the latest news on NCEL?

The most recent item we track (GlobeNewsWire, 28 Sept 2026): "NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes". NewCelX Ltd. management plans to attend the Breakthrough T1D Congress in Philadelphia, a step supporting the company's mission to develop a cure for Type 1 diabetes. The announcement was made via press release from Zurich on Sept. 28, 2026.

Company

About NewCelX Ltd.

NewcelX Ltd. is a Switzerland-based biopharmaceutical company focused on developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. Its current portfolio centers on stem-cell-derived and off-the-shelf regenerative medicine programs, including therapies for Type 1 diabetes, insulin-dependent Type 2 diabetes, amyotrophic lateral sclerosis, and other neurological conditions. The company’s work combines cell replacement, neuroscience, and translational research to address areas with significant unmet medical need. NewcelX Ltd. also develops a dual orexin-receptor agonist platform for sleep disorders and related neurological indications, reflecting a broader approach across metabolic, inflammatory, and central nervous system disorders. Headquartered in Kloten, Switzerland, NewcelX Ltd. operates as a clinical-stage biotechnology firm with research and development activities supporting its therapeutic pipeline.

CEO Mr. Ronen Twito CPA · 9 employees · Switzerland · https://newcelx.com